CompletedNot Applicable

Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)

France50 participantsStarted 2020-12-01

Plain-language summary

Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes occurring along the optic nerve of the brain parenchyma. Indeed, our team has been able to develop a quantitative method to measure the perivascular infiltrate in the retina of patients with various inflammatory retinal disease. It has been observed in MS patients that this perivascular infiltrate can also be detected in the retina. However, its distribution across MS phenotypes (relapsing or progressive MS, with and without optic neuritis) is still unknown.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Group 1: * Age between 18 and 60 years old. * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject who has never presented a clinical episode of optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 2: * Age between 18 and 60 years old * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject presenting an acute episode of retrobulbar optic neuritis within 3 months from onset * After optimal treatment for the retrobulbar optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 3: * Age between 18 and 60 years old * Primary or Secondary progressive multiple sclerosis within 10 years of progressive phase; * Affiliation to a social security scheme or beneficiary of such a scheme Group 4 (Healthy Subjects): * Age between 18 and 60 years old * Affiliation to a social security scheme or beneficiary of such a scheme Exclusion Criteria: For all patients (Group 1; 2; 3): * Corticosteroid treatment within one month from inclusion * Other neurological, ophthalmologic or systemic disease; * Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion) * Severe renal dysfunction (glomerular filtration rate \< 30mL/min). This non-inclusion criteria will be verified by serum creat…

What they're measuring

Quantification of retinal perivascular cuff width across MS phenotypes

Timeframe: Baseline

Trial details

NCT IDNCT04289909

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-06-26